Experimental cancer drug KD033 tested in Early-Stage trial
NCT ID NCT04242147
First seen Oct 31, 2025 · Last updated May 22, 2026 · Updated 29 times
Summary
This early-stage study tested an experimental drug called KD033 (SAR445710) in 45 adults with advanced solid tumors that had spread. The main goal was to check the drug's safety at different doses and see how the body processes it. The study also looked for any anti-cancer effects. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fox Chase Cancer Center - 333 Cottman Avenue - Site 141
Philadelphia, Pennsylvania, 19111, United States
-
Moffitt Cancer Center - Site 102
Tampa, Florida, 33612, United States
-
Roswell Park Cancer Institute - 665 Elm St - Site 062
Buffalo, New York, 14263, United States
-
UCLA Hematology/Oncology, 2020 Santa Monica Boulevard, Suite 600 - Site 042
Santa Monica, California, 90404, United States
-
University of Pittsburgh Medical Center - Hillman Cancer Center - 5150 Centre Avenue, Suite 301 - Site 132
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.